XML 65 R35.htm IDEA: XBRL DOCUMENT
v3.20.1

License Agreements (Details) € in Millions | 3 Months Ended |  |  |
--- | --- | --- | --- | ---
Mar. 31, 2020 USD ($) | Mar. 31, 2019 USD ($) | Mar. 31, 2020 EUR (€) | Mar. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Nov. 01, 2019 USD ($)
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Research and development | $ 42,042,000 | $ 23,403,000 |  |  |  |  |
Accrued and other current liabilities |  |  |  | $ 19,619,000 | $ 23,829,000 | [1] |
Equity method investment |  |  |  | $ 4,829,000 | 4,892,000 | [1] |
Research and development |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Collaboration arrangement, expense | $ 300,000 |  |  |  |  |  |
Notch Therapeutics, Inc. |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Equity method investment |  |  |  |  | 4,900,000 |  | $ 5,000,000.0
Ownership percentage |  |  | 25.00% | 25.00% |  |  | 25.00%
Pfizer |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Royalty obligation period from date of first sale | 12 years |  |  |  |  |  |
Pfizer | Asset Contribution Agreement |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Aggregate potential milestone payments | $ 325,000,000.0 |  |  |  |  |  |
Pfizer | Asset Contribution Agreement | Minimum |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Aggregate potential milestone payments | 30,000,000.0 |  |  |  |  |  |
Pfizer | Asset Contribution Agreement | Maximum |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Aggregate potential milestone payments | 60,000,000.0 |  |  |  |  |  |
Aggregate potential regulatory and development milestones | 840,000,000.0 |  |  |  |  |  |
Cellectis | Research Collaboration and License Agreement |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Maximum payments required per product against selected target | 185,000,000.0 |  |  |  |  |  |
Cellectis | Research Services | Research Collaboration and License Agreement |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Research and development | 0 | 0 |  |  |  |  |
Cellectis | Pre-Clinical Development Milestone | Research Collaboration and License Agreement |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Research and development | 0 | 0 |  |  |  |  |
Cellectis | Development and Sales | Maximum | Research Collaboration and License Agreement |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Aggregate potential milestone payments | $ 2,800,000,000 |  |  |  |  |  |
Servier | License and Collaboration Agreement |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Research and development |  | $ 700,000 |  |  |  |  |
Percentage of development costs payable by the Company | 60.00% |  |  |  |  |  |
Percentage of development cost payable by collaboration partner | 40.00% |  |  |  |  |  |
Recovery of research and development expense | $ 1,000,000.0 |  |  |  |  |  |
Receivables |  |  |  | $ 200,000 |  |  |
Accrued and other current liabilities |  |  |  |  | $ 2,200,000 |  |
Servier | Regulatory Milestone | License and Collaboration Agreement |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Aggregate potential milestone receivable |  |  |  | 42,000,000 |  |  |
Servier | Regulatory Milestone | Maximum | License and Collaboration Agreement |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Aggregate potential milestone payments | 137,500,000 |  |  |  |  |  |
Servier | Sales Milestone | License and Collaboration Agreement |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Aggregate potential milestone receivable |  |  | € 70.5 | 77,400,000 |  |  |
Servier | Sales Milestone | Maximum | License and Collaboration Agreement |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Aggregate potential milestone payments | 78,000,000.0 |  |  |  |  |  |
Notch Therapeutics, Inc. | Research Collaboration and License Agreement |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Aggregate potential milestone payable |  |  |  | $ 7,250,000 |  |  |
Notch Therapeutics, Inc. | License and Collaboration Agreement |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Research and development | 10,000,000 |  |  |  |  |  |
Collaboration agreement, upfront payment |  |  |  |  |  |  | $ 10,000,000.0
Notch Therapeutics, Inc. | Pre-Clinical Development Milestone | Maximum | License and Collaboration Agreement |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Aggregate potential milestone payments | 4,000,000.0 |  |  |  |  |  |
Notch Therapeutics, Inc. | Clinical, Regulatory, and Commercial Milestone | Maximum | License and Collaboration Agreement |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Aggregate potential milestone payments | $ 283,000,000.0 |  |  |  |  |  |
[1] | The balance sheet as of December 31, 2019 is derived from the audited financial statements as of that date.

X
- Definition Accrued and other current liabilities. + References No definition available. + Details
Name: | allo_AccruedAndOtherLiabilitiesCurrent
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate potential milestone payable + References No definition available. + Details
Name: | allo_AggregatePotentialMilestonePayable
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate potential milestone payments. + References No definition available. + Details
Name: | allo_AggregatePotentialMilestonePayments
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate potential milestone receivable. + References No definition available. + Details
Name: | allo_AggregatePotentialMilestoneReceivable
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate potential regulatory and development milestones. + References No definition available. + Details
Name: | allo_AggregatePotentialRegulatoryAndDevelopmentMilestones
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreement, Upfront Payment + References No definition available. + Details
Name: | allo_CollaborationAgreementUpfrontPayment
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration Arrangement, Expense + References No definition available. + Details
Name: | allo_CollaborationArrangementExpense
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum payments required per product against selected target. + References No definition available. + Details
Name: | allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments. + References No definition available. + Details
Name: | allo_MilestonePayments
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage Of Development Cost Payable By Related Party + References No definition available. + Details
Name: | allo_PercentageOfDevelopmentCostPayableByCollaborationPartner
Namespace Prefix: | allo_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage Of Development Cost Payable By The Company + References No definition available. + Details
Name: | allo_PercentageOfDevelopmentCostPayableByTheCompany
Namespace Prefix: | allo_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Recovery Of Research And Development Expense + References No definition available. + Details
Name: | allo_RecoveryOfResearchAndDevelopmentExpense
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty Obligation Period From Date Of First Sale + References No definition available. + Details
Name: | allo_RoyaltyObligationPeriodFromDateOfFirstSale
Namespace Prefix: | allo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(9)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(5)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 + Details
Name: | us-gaap_AccountsReceivableNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of investment in equity method investee and investment in and advance to affiliate. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=allo_AssetContributionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=allo_ResearchCollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=allo_ResearchServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=allo_PreClinicalDevelopmentMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | allo_MilestoneTypeAxis=allo_DevelopmentAndSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=allo_LicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=allo_RegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=allo_SalesMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=allo_ClinicalRegulatoryAndCommercialMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |